Table 1. The CLDN1-specific antibody is efficient in inhibiting HCV spread.

Treatment	Percentage of HCV positive cells
mock	96±2%
anti-CLDN1	10±2%
telaprevir	20±3%
daclatasvir	15±3%

The spread assay was performed as shown in Figure 3 and Figure S3. The data are pooled and represented as mean ± SD form three experiments performed in triplicate.